



Unilife Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

YORK, Pa., Feb. 5, 2015 - Unilife Corporation ("Unilife") (NASDAQ: UNIS, ASX: UNS), a leading developer and supplier of injectable drug delivery systems, today announced the closing of its previously announced public offering in the United States of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an additional 1,650,000 shares of common stock. As a result, Unilife issued a total of 12,650,000 shares in the offering at a public price of \$3.75 per share.

The net proceeds from the offering to Unilife are expected to be \$44.7 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Unilife. Jefferies LLC and Piper Jaffray & Co. acted as joint book-running managers for the offering. Griffin Securities, Inc. acted as a co-manager for the offering.

Unilife expects to use the net proceeds of the offering for investments in Unilife's plant, equipment, systems and personnel to further develop its manufacturing and operational capabilities to satisfy current and future customer orders and general corporate purposes, including working capital, acquisitions and other business opportunities.

A prospectus supplement relating to the offering has been filed with the Securities and Exchange Commission (the "SEC") and is available on the SEC's website at <http://www.sec.gov>. Copies of the prospectus supplement and accompanying base prospectus relating to the offering may also be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd floor, New York, NY 10022 or by telephone at 877-547-6340 or by email at Prospectus_Department@Jefferies.com; or Piper Jaffray & Co. by mail at 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by e-mail at prospectus@pjc.com.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Unilife Corporation

Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a leading developer and supplier of injectable drug delivery systems. Unilife's portfolio of innovative, differentiated products includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems. Products within each platform are customizable to address specific customer, drug and patient requirements. Unilife's global headquarters and manufacturing facilities are located in York, PA. For more information, visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

General: UNIS-G

Unilife Corporation ARBN: 141 042 757

A corporation with limited liability incorporated in Delaware, USA

250 Cross Farm Lane, York PA 17406 T + 1 717 384 3400 F + 717 384 3401 E info@unilife.com W www.unilife.com

Forward-Looking Statements

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including statements regarding Unilife's expectations with respect to the offering and the anticipated use of proceeds therefrom. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

Investor / PR Contacts (US):

Todd Fromer / Garth Russell
KCSA Strategic Communications
P: + 1 212-682-6300

Analyst Enquiries

Lynn Piper
Westwicke Partners
P: + 1 415-513-1281

Investor Contacts (Australia)

Jeff Carter
Unilife Corporation
P: + 61 2 8346 6500

Unilife Corporation

250 Cross Farm Lane, York PA 17406 **T** + 1 717 384 3400 **F** + 717 384 3401 **E** info@unilife.com **W** www.unilife.com